Tokio Marine Asset Management Co. Ltd. Increases Stake in Humana Inc. (NYSE:HUM)

Tokio Marine Asset Management Co. Ltd. increased its stake in Humana Inc. (NYSE:HUM) by 13.5% in the 3rd quarter, Holdings Channel.com reports. The firm owned 3,249 shares of the insurance provider’s stock after buying an additional 386 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Humana were worth $1,029,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of HUM. Mendota Financial Group LLC grew its position in Humana by 9.2% during the second quarter. Mendota Financial Group LLC now owns 319 shares of the insurance provider’s stock valued at $119,000 after acquiring an additional 27 shares during the last quarter. Capital Advisors Ltd. LLC lifted its stake in shares of Humana by 17.0% in the second quarter. Capital Advisors Ltd. LLC now owns 213 shares of the insurance provider’s stock worth $80,000 after buying an additional 31 shares in the last quarter. CarsonAllaria Wealth Management Ltd. boosted its holdings in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after purchasing an additional 39 shares during the last quarter. Harbour Investments Inc. grew its holdings in shares of Humana by 10.5% in the second quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock worth $161,000 after acquiring an additional 41 shares during the period. Finally, Baader Bank Aktiengesellschaft raised its position in Humana by 1.0% in the second quarter. Baader Bank Aktiengesellschaft now owns 4,421 shares of the insurance provider’s stock worth $1,649,000 after acquiring an additional 42 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Stock Performance

Shares of HUM opened at $275.67 on Friday. The stock has a market capitalization of $33.19 billion, a PE ratio of 24.42, a price-to-earnings-growth ratio of 2.29 and a beta of 0.52. The business’s fifty day moving average price is $283.00 and its 200 day moving average price is $331.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Equities research analysts forecast that Humana Inc. will post 15.83 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.28%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s dividend payout ratio (DPR) is currently 31.36%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. KeyCorp assumed coverage on Humana in a report on Friday, October 11th. They issued a “sector weight” rating on the stock. Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective on the stock in a research report on Tuesday, October 8th. UBS Group dropped their price target on Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Barclays lifted their target price on shares of Humana from $250.00 to $253.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Finally, Leerink Partnrs cut shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Twenty equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.